Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate

Journal of Rheumatology

Volumn 39, Issue 4, 2012, Pages 720-727

  Stock, Thomas C ^a   Bloom, Bradley J ^b   Wei, Nathan ^c   Ishaq, Saliha ^d   Park, Won ^e   Wang, Xin ^a   Gupta, Pankaj ^a   Mebus, Charles A ^a  

^a PFIZER INC   (United States)

^b SHIRE   (United States)

^c Arthritis Treatment Center   (United States)

^d Northshore Rheumatology   (United States)

^e Inha University Hospital   (South Korea)

Author keywords

Interleukin 1; Interleukin 18; Purinergic P2X7 receptor; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CE 224535; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HYDROCODONE; METHOTREXATE; OXYCODONE; PARACETAMOL; PLACEBO; PURINERGIC P2X7 RECEPTOR; TRAMADOL;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTICLE; BRONCHITIS; CONTROLLED STUDY; CYTOKINE RESPONSE; DIARRHEA; DISABILITY SEVERITY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INSOMNIA; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; THROMBOCYTOPENIA; UPPER ABDOMINAL PAIN; VOMITING;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BENZAMIDES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; PURINERGIC P2X RECEPTOR ANTAGONISTS; URACIL; YOUNG ADULT;

EID: 84859456520     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110874     Document Type: Article

References (32)

1. Abell JE, Hootman JM, Zack MM, Moriarty D, Helmick CG. Physical activity and health related quality of life among people with arthritis. J Epidemiol Community Health 2005;59:380-5. (Pubitemid 40559199)
2. Bathon JM, Cohen SB. The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: Where the rubber meets the road. Arthritis Rheum 2008;59:757-9. (Pubitemid 351847557)
3. American College of Rheumatology Subcommittee on Rheumatoid Arthritis. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
4. Jobanputra P, Wilson J, Douglas K, Burls A. A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. Rheumatology 2004;43:206-10. (Pubitemid 38219677)
5. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. (Pubitemid 351847559)
6. Cohen SB, Cohen MD, Cush JJ, Fleischmann RM, Mease PJ, Schiff MH, et al. Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: Weighing the evidence. J Rheumatol Suppl. 2008 Feb;81:4-30.
7. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-86.
8. Bykerk V. Unmet needs in rheumatoid arthritis. J Rheumatol Suppl. 2009 June;82:42-6.
9. Collo G, Neidhart S, Kawashima E, Kosco-Vilbois M, North RA, Buell G. Tissue distribution of the P2X7 receptor. Neuropharmacology 1997;36:1277-83.
10. Lister MF, Sharkey J, Sawatzky DA, Hodgkiss JP, Davidson DJ, Rossi AG, et al. The role of the purinergic P2X7 receptor in inflammation. J Inflamm 2007;4:5.
11. Sluyter R, Dalitz JG, Wiley JS. P2X7 receptor polymorphism impairs extracellular adenosine 5′-triphosphate-induced interleukin-18 release from human monocytes. Genes Immun 2004;5:588-91. (Pubitemid 39529976)
12. López-Castejón G, Young MT, Meseguer J, Surprenant A, Mulero V. Characterization of ATP-gated P2X7 receptors in fish provides new insights into the mechanism of release of the leaderless cytokine interleukin-1 beta. Mol Immunol 2007;44:1286-99. (Pubitemid 44415965)
13. Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, et al. The P2X7 receptor: A key player in IL-1 processing and release. J Immunol 2006;176:3877-83. (Pubitemid 44264361)
14. North RA. Molecular physiology of P2X receptors. Physiol Rev 2002;82:1013-67.
15. Surprenant A, Rassendren F, Kawashima E, North RA, Buell G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 1996;272:735-8.
16. Kay J, Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology 2004;43 Suppl 3:iii2-iii9.
17. John T, Kohl B, Mobasheri A, Ertel W, Shakibaei M. Interleukin-18 induces apoptosis in human articular chondrocytes. Histol Histopathol 2007;22:469-82. (Pubitemid 46647261)
18. Shao XT, Feng L, Gu LJ, Wu LJ, Feng TT, Yang YM, et al. Expression of interleukin-18, IL-18BP, and IL-18R in serum, synovial fluid, and synovial tissue in patients with rheumatoid arthritis. Clin Exp Med 2009;9:215-21.
19. Kavanaugh A. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. Adv Ther 2006;23:208-17. (Pubitemid 43876665)
20. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: A systematic review. J Rheumatol 2009;36:1118-25.
21. Waugh J, Perry CM. Anakinra: A review of its use in the management of rheumatoid arthritis. BioDrugs 2005;19:189-202.
22. Khraishi M. Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol Suppl. 2009 June;82:25-32.
23. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;CD007848.
24. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24. (Pubitemid 34214243)
25. Romagnoli R, Baraldi PG, Cruz-Lopez O, Lopez-Cara C, Preti D, Borea PA, et al. The P2X7 receptor as a therapeutic target. Expert Opin Ther Targets 2008;12:647-61.
26. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH, et al. Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem 2001;276:125-32. (Pubitemid 32050297)
27. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
28. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42. (Pubitemid 46834849)
29. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-905.
30. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010;69:88-96.
31. Haas CE, Kaufman DC, Jones CE, Burstein AH, Reiss W. Cytochrome P450 3A4 activity after surgical stress. Crit Care Med 2003;31:1338-46. (Pubitemid 36583841)
32. Rivory LP, Slaviero KA, Clarke SJ. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 2002;87:277-80.